الفهرس 
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)Only 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Fatty liver disease includes a spectrum of disorders ranging from simple steatosis or non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), to cirrhosis.
The prevalence of NAFLD varies between 19%and 33%in different populations, nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, the second leading cause of liver transplantation.
Many individuals have risk factors associated with NAFLD, the major risk factors associated with increased prevalence of NAFLD are being male, increasing age, ethnicity, hypertension, hypercholesterolemia, diabetes mellitus, lower socio-economic level, lower educational level, and lower physical activity.
The NAFLD fibrosis score is a validated, noninvasive tool for identifying patients whose NAFLD has advanced to liver fibrosis. in patients with a high NAFLD fibrosis score, additional testing such as Enhanced Liver Fibrosis (ELF) score, elastography, or liver biopsy may be considered.
At present, there is no registered drug for the treatment of NASH. While lifestyle management is often encouraged, but it is difficult to maintain.